TearSolutions' lead product, called Lacripep, delivers what no other approved or pipeline drug has been able to: rapid healing of the ocular surface and relief of dry eye symptoms with a best-in-class safety and comfort profile. This was all proven in their first-in-human clinical trial which has led to formal written FDA alignment on our clinical and regulatory path to an unrestricted general Dry Eye indication (which is the same path a dry eye drug called Xiidra took, which sold to Novartis for $5.3B).
The company is raising capital to get Lacripep back into the clinic for the first of two Phase III trials.
Jaffar Raza, MD is a board certified Interventional Cardiologist affiliated with Lenox Hill, Hackensack and Holy name hospitals. He completed his residency in Internal...
Dr. Gupta is very active working with innovative startups across medical device and digital health and serves as a Sr. Clinical Advisor with AngelMD...
One of the most creative, insightful and articulate startup leaders in the industry, Matan Magril is always fascinating to talk with. At 22, he...
